**Breakthrough Chinese Monoclonal ADC Targets Nectin-4: Achieving 91.9% Disease Control Rate Across Multiple Solid Tumors**

Monoclonal ADC

#MonoclonalADC #Nectin4 #Solidtumor #9MW2821 #cervicalcancer #urothelialcarcinoma #esophagealcancer #breastcancer

Meet 9MW2821, a groundbreaking monoclonal antibody-drug conjugate (ADC) developed in China that targets Nectin-4, an adhesion molecule highly expressed in several solid tumors, including cervical cancer (CC), urothelial carcinoma (UC), esophageal cancer (EC), and breast cancer. Recently, this innovative therapy was granted Breakthrough Therapy Designation by the China Center for Drug Evaluation (CDE) for treating locally advanced or metastatic urothelial carcinoma, specifically in patients who have previously failed platinum-based chemotherapy and PD-(L)1 inhibitors.

The latest clinical results were unveiled at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the remarkable efficacy of 9MW2821 in a Phase 1/2 trial involving 260 patients with various advanced solid tumors. These included UC, triple-negative breast cancer (TNBC), EC, and CC. Among 37 evaluable UC patients, the disease control rate (DCR) soared to an impressive 91.9%, with an objective response rate (ORR) of 62.2%. Additionally, the median overall survival (mOS) reached 14.2 months, while the median progression-free survival (mPFS) was 8.8 months.

This promising therapy is poised to redefine treatment paradigms for patients with advanced solid tumors who have limited options, marking a significant milestone in the global oncology landscape.

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

5 months ago CAR-T

AACR 2024/Breakthrough Chinese Research – Monotherapy for Late-stage #SolidTumors and #Lymphomas

AACR 2024/Breakthrough Chinese Research – Monotherapy for Late-stage #SolidTumors and #Lymphomas

AACR2024

#AACR2024

At the 2024 American Association for Cancer Research (#AACR) Annual Meeting, innovative drugs from China showed promising safety and preliminary efficacy in early clinical trials, attracting high interest from attending experts and researchers, showcasing the strength of #Chineseresearch teams in new drug development.

#TQB2916

A groundbreaking focus of cancer research is on #TQB2916, the latest #CD40 agonist antibody causing a stir in the medical field.

#CD40

 receptors, a member of the tumor necrosis factor receptor family, play a vital role in immune responses. TQB2916, a humanized IgG2 CD40 monoclonal antibody, has demonstrated CD40 activation and promising anti-tumor activity in preclinical studies. With its potential to revolutionize cancer treatment, TQB2916 is currently undergoing its first human study for late-stage solid tumors and lymphomas, led by the team at Tianjin Medical University Cancer Institute & Hospital.

#ECOG

Now, let’s delve into the details: Eligible patients, including those with an ECOG performance status of 0 or 1, adequate hematologic and organ function, and no response to standard treatments, are enrolled. TQB2916 is administered intravenously every 3 weeks until disease progression or unacceptable toxicity. The study utilizes a Bayesian Optimal Interval (BOIN) design to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D). The primary objectives are to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TQB2916.

#Realcase

From April 2022 to November 2023, a total of 18 patients with solid tumors and 2 with lymphomas underwent TQB2916 monotherapy and were assigned to 7 dose cohorts. Adverse events were observed, with the most common including lipase increase, amylase increase, lymphocyte count decrease, ALT increase, ALP elevation, AST elevation, hypoalbuminemia, and anorexia. However, most adverse events were manageable, primarily Grade 1 or 2 severity.

#Lymphomas

Of the 16 evaluated patients, 3 achieved stable disease according to immune RECIST criteria for solid tumors and LYRIC criteria for lymphomas. Pharmacokinetic analyses showed favorable performance, with no drug accumulation upon repeat dosing. Additionally, dose-dependent occupancy of CD40 receptors was detected, alongside peripheral B cell reduction and increased cytokine secretion.

#Conclusion

TQB2916 achieves CD40 engagement and immune activation through cytokine modulation. With its promising safety and efficacy profile, 200mg has been identified as the preliminary expansion dose. Studies exploring TQB2916 in combination with immune checkpoint inhibitors and/or other anti-cancer therapies are currently underway.

Stay tuned for more updates on this groundbreaking treatment!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:

doctor.huang@globecancer.com

WhatsApp +86137 1795 9070

The Medical Department will contact you as soon as they receive the reports.

#CancerResearch #Immunotherapy #MedicalBreakthrough #AACR22024 #chinesemedical

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

7 months ago CAR-T

TIL Therapy: Revolutionizing Cancer Treatment Worldwide! China Accelerates into the Fast Lane!

🌟 **TIL Therapy: Revolutionizing Cancer Treatment Worldwide! 🌎** China Accelerates into the Fast Lane!

 

📈 The number of cell immunotherapy trials for solid tumor treatment has surged globally, with a staggering growth from 66 in 2020 to 140 in 2022, a remarkable 110% increase! Particularly, TIL therapy trials have seen a remarkable surge, now accounting for 17.1% of all solid tumor treatments, sparking a new trend in cancer therapy that’s capturing the attention of researchers and companies alike.

 

🎯 TIL therapy boasts natural advantages in solid tumor treatment, boasting rich tumor-specific target points, robust tumor infiltration capabilities, and minimal side effects.

 

🔬 On February 16, 2024, the U.S. FDA officially greenlights Iovance Biotherapeutics’ lifileucel therapy for unresectable or metastatic melanoma, a groundbreaking personalized T-cell therapy using TIL sourced from the patient’s body.

 

FDA

🚀 In early 2022, China’s Grit Biotechnology’s GT101 injection became the first TIL product to enter clinical trials, signaling China’s entry into the global TIL therapy scene. With players like Juncell Therapeutics, LANMA BIO, and BT Gillion joining the fray, Chinese TIL therapy is on the fast track to development, exploring various indications including melanoma, cervical cancer, lung cancer, and more!

TIL therapy

 

💰 According to Sullivan’s forecast, the global CGT market is set to skyrocket to $22 billion by 2025, with TIL therapy leading the charge.

 

💡 Chinese TIL therapy is paving its own path to commercialization and industrialization, offering cost-effective treatments compared to the U.S. Stay tuned for more innovations in cancer therapy from China! 🇨🇳

 

🌟We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.

doctor.huang@globecancer.com

WhatsApp+8613717959070

 

#TILTherapy #CancerTreatment #Innovation #MedicalBreakthroughs #ChinaHealthcare #GlobalHealthcare #CancerResearch 🚀🔬